Clinical trial
Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases
NCT01823003 is registered in ClinicalTrials.gov with Institut Català d'Oncologia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases
- Lead sponsor
- Institut Català d'Oncologia
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2012
- Completion date
- July 31, 2020
- Enrollment
- 67 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.